Atsushi Ohtsu Selected Research

Capecitabine (Xeloda)

10/2022	Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial.
5/2018	Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm.
7/2014	Quality of life in the trastuzumab for gastric cancer trial.
4/2013	Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study.
4/2012	Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer.
10/2011	Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Atsushi Ohtsu Research Topics

Disease

121	Neoplasms (Cancer) 09/2023 - 08/2000
80	Stomach Neoplasms (Stomach Cancer) 09/2023 - 08/2000
54	Colorectal Neoplasms (Colorectal Cancer) 05/2023 - 01/2003
21	Adenocarcinoma 10/2021 - 12/2004
21	Neutropenia 10/2018 - 06/2004
19	Esophageal Squamous Cell Carcinoma 10/2022 - 06/2006
18	Esophageal Neoplasms (Esophageal Cancer) 10/2021 - 01/2002
16	Disease Progression 05/2020 - 09/2000
14	Neoplasm Metastasis (Metastasis) 06/2017 - 08/2000
10	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/2017 - 05/2002
9	Colonic Neoplasms (Colon Cancer) 10/2022 - 02/2011
8	Carcinoma (Carcinomatosis) 01/2017 - 05/2002
7	Febrile Neutropenia 03/2018 - 02/2008
7	Leukopenia 03/2018 - 02/2008
6	Breast Neoplasms (Breast Cancer) 01/2023 - 01/2006
6	Diarrhea 01/2023 - 06/2004
6	Anorexia 10/2022 - 04/2009
6	Nausea 01/2018 - 04/2009
6	Pathologic Constriction (Stenosis) 01/2018 - 05/2002
5	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 02/2013 - 08/2003
4	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2023 - 08/2003
4	Proteinuria 10/2020 - 01/2009
4	Fatigue 01/2018 - 10/2014
4	Vomiting 01/2017 - 08/2010
4	Squamous Cell Carcinoma of Head and Neck 10/2012 - 10/2002
3	Exanthema (Rash) 10/2022 - 03/2014
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2021 - 01/2017
3	Hypertension (High Blood Pressure) 03/2018 - 10/2014
3	Hemorrhage 01/2018 - 04/2002
3	Ascites 01/2018 - 06/2004
3	Thrombocytopenia (Thrombopenia) 01/2017 - 06/2015
3	Hyperglycemia 08/2015 - 10/2012
3	Deglutition Disorders (Dysphagia) 10/2012 - 05/2002
3	Anemia 10/2011 - 06/2004
2	Hyponatremia 10/2022 - 04/2010

Drug/Important Bio-Agent (IBA)

41	Fluorouracil (Carac)FDA LinkGeneric 10/2022 - 08/2000
34	Irinotecan (Camptosar)FDA LinkGeneric 01/2017 - 08/2000
28	Cisplatin (Platino)FDA LinkGeneric 05/2021 - 09/2000
22	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2002
16	Oxaliplatin (Eloxatin)FDA LinkGeneric 10/2022 - 08/2003
14	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 08/2000
13	Trastuzumab (Herceptin)FDA Link 01/2023 - 08/2010
13	RamucirumabIBA 01/2021 - 10/2014
13	trifluridine tipiracil drug combinationIBA 12/2018 - 10/2012
11	Monoclonal AntibodiesIBA 10/2019 - 01/2006
10	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2020 - 01/2002
9	Leucovorin (Folinic Acid)FDA Link 10/2022 - 04/2006
9	PlatinumIBA 10/2021 - 01/2009
7	Bevacizumab (Avastin)FDA Link 05/2018 - 10/2010
7	Formaldehyde (Formol)FDA Link 01/2016 - 01/2002
7	ErbB Receptors (EGF Receptor)IBA 01/2016 - 01/2002
6	pembrolizumabIBA 09/2023 - 01/2018
6	Capecitabine (Xeloda)FDA Link 10/2022 - 10/2011
6	human ERBB2 proteinIBA 11/2021 - 08/2010
6	Cetuximab (Erbitux)FDA Link 05/2021 - 06/2009
6	ParaffinIBA 01/2016 - 01/2006
5	pertuzumabIBA 01/2023 - 10/2018
5	NivolumabIBA 10/2021 - 01/2017
5	S-1 plus cisplatinIBA 05/2021 - 02/2011
5	Proteins (Proteins, Gene)FDA Link 12/2018 - 01/2006
5	Everolimus FDA Link 01/2017 - 01/2010
5	Methotrexate (Mexate)FDA LinkGeneric 10/2013 - 08/2000
5	Imatinib Mesylate (Gleevec)FDA Link 02/2013 - 08/2003
5	Thymidylate SynthaseIBA 01/2011 - 01/2002
4	AntibodiesIBA 11/2017 - 01/2011
4	regorafenibIBA 01/2017 - 06/2015
4	Docetaxel (Taxotere)FDA Link 07/2016 - 01/2002
4	Mitomycin (Mitomycin-C)FDA LinkGeneric 09/2012 - 01/2003
3	B7-H1 AntigenIBA 09/2023 - 10/2018
3	DNA (Deoxyribonucleic Acid)IBA 10/2019 - 01/2011
3	Ado-Trastuzumab EmtansineIBA 01/2019 - 10/2016
3	taxaneIBA 01/2019 - 01/2017
3	Antineoplastic Agents (Antineoplastics)IBA 01/2018 - 08/2000
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 10/2016 - 02/2015
3	1-phenyl-3,3-dimethyltriazene (PDT)IBA 06/2016 - 09/2012
3	Tyrosine Kinase InhibitorsIBA 10/2015 - 09/2006
3	Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)IBA 10/2015 - 01/2002
3	Insulin (Novolin)FDA Link 08/2015 - 09/2013
3	TOR Serine-Threonine KinasesIBA 11/2013 - 04/2010
3	Sunitinib (Sutent)FDA Link 03/2012 - 12/2010
3	TegafurIBA 11/2009 - 01/2003
3	Doxorubicin (Adriamycin)FDA LinkGeneric 06/2005 - 08/2000
3	Glucuronosyltransferase (UDP Glucuronosyltransferase)IBA 04/2005 - 01/2002
2	Phosphotransferases (Kinase)IBA 05/2023 - 01/2014
2	NVP-BKM120IBA 10/2022 - 03/2014
2	Circulating Tumor DNAIBA 11/2021 - 12/2020
2	afliberceptIBA 10/2020 - 08/2013

Therapy/Procedure

77	Drug Therapy (Chemotherapy) 01/2023 - 09/2000
69	Therapeutics 09/2023 - 08/2000
34	Chemoradiotherapy 06/2017 - 01/2002
8	Radiotherapy 04/2011 - 04/2003
6	Adjuvant Chemotherapy 11/2019 - 09/2000
5	Salvage Therapy 06/2016 - 07/2003
4	Neoadjuvant Therapy 06/2017 - 01/2003
4	Photochemotherapy (Photodynamic Therapy) 06/2016 - 07/2005
3	Induction Chemotherapy 07/2016 - 02/2008
3	Combination Drug Therapy (Combination Chemotherapy) 12/2013 - 02/2006
3	Esophagectomy 10/2012 - 07/2003
3	Endoscopes 10/2012 - 02/2003
3	Gastrectomy 06/2005 - 09/2000